Abstract
A major issue for present HIV-1 research is to establish model systems that reflect or mimic viral replication and pathogenesis actually observed in infected humans. To this end, various strategies using macaques as infection targets have long been pursued. In particular, experimental infections of rhesus macaques by HIV-1 derivatives have been believed to be best suited, if practicable, for studies on interaction of HIV-1 and humans under various circumstances. Recently, through in vitro genetic manipulations and viral cell-adaptations, we have successfully generated a series of HIV-1 derivatives with CXCR4-tropism or CCR5-tropism that grow in macaque cells to various degrees. Of these viruses, those with best replicative potentials can grow comparably with a pathogenic SIVmac in macaque cells by counteracting major restriction factors TRIM5, APOBEC3, and tetherin proteins. In this study, rhesus macaques were challenged with CXCR4-tropic (MN4/LSDQgtu) or CCR5-tropic (gtu + A4CI1) virus. The two viruses were found to productively infect rhesus macaques, being rhesus macaque-tropic HIV-1 (HIV-1rmt). However, plasma viral RNA was reduced to be an undetectable level in infected macaques at 5–6 weeks post-infection and thereafter. While replicated similarly well in rhesus peripheral blood mononuclear cells, MN4/LSDQgtu grew much better than gtu + A4CI1 in the animals. To the best of our knowledge, this is the first report demonstrating that HIV-1 derivatives (variants) grow in rhesus macaques. These viruses certainly constitute firm bases for generating HIV-1rmt clones pathogenic for rhesus monkeys, albeit they grow more poorly than pathogenic SIVmac and SHIV clones reported to date.
Introduction
HIV-1 has emerged from ancestral viruses by extensive recombination and/or adaptation events (). It exhibits an exquisitely complicated replication format, about which much remains to be precisely clarified (; ; ; ; ; ; ; ; ; ; ; Yamashita and Engelman, 2017; ). HIV-1 is highly adapted to humans in nature, and thus strictly tropic only for humans and chimpanzees. Following infection, HIV-1 persists in humans, and after lengthy persistent state, ultimately causes AIDS-related diseases and AIDS in most cases if not treated appropriately. Due to the exceptionally narrow host range of HIV-1, primarily based on its sophisticatedly regulated replication, animal models for experimental infections have been difficult to develop from the dawn period to the present stage of HIV-1 research. Ambitious attempts to establish in vivo systems effective and potent for model studies on HIV-1 continue to be one of major approaches toward basic and clinical studies on HIV-1 and AIDS.
A number of animal models have been proposed and tested so far to perform in vivo studies on HIV-1 (; , ; ; ). Surrogate models for HIV-1 infection in humans include feline immunodeficiency virus (FIV) in cats and simian immunodeficiency virus isolated from the rhesus macaque (SIVmac) infection in macaques (; Slee et al., 1995; Veazey et al., 1998; ; Sparger, 2006; ; ; ). Of note, the SIVmac/macaque system has been frequently and widely used for various study purposes, but not the FIV/cat model (). As for the other animal models, because none of experimental animals are susceptible to HIV-1 infection as described above, challenge viruses and/or host animals need to be artificially manipulated. Small animal model systems, i.e., transgenic mice/HIV-1, transgenic rats/HIV-1, and transgenic rabbits/HIV-1, have been unsuccessful due to the lack of robust HIV-1 replication and/or disease progression (; ; ; ). Exception is the humanized mouse model (human immune system mouse model). A number of humanized mouse models have been generated and extensively used for HIV-1 research (). However, there is clearly an unavoidable limitation for the humanized mouse system. Since humanized mice cannot have a complete functional human immune system (cellular and humoral acquired immunity), they cannot reproduce typical features of HIV-1 replication and pathogenesis in vivo in response to HIV-1 infection. As an alternative for SIVmac in the macaque system, a chimeric virus designated SHIV has been extensively and successfully utilized for input virus for experimental infection of macaques since its initial description by us (Shibata et al., 1991; ; Shibata and Adachi, 1992). SHIVs are genetically engineered virus clones that basically carry the env (Shibata et al., 1991), pol-reverse transcriptase (RT) (Uberla et al., 1995), or pol-protease () gene of HIV-1 in the backbone of SIVmac genome. An SHIV carrying HIV-1 pol-RT and Env also has been constructed (Smith et al., 2010). Of these SHIVs, Env-SHIV has been most widely and successfully used, especially for immunotherapy research for HIV-1 ().
Macaque-Tropic HIV-1 Derivative Clones
To experimentally and demonstratively perform studies on HIV-1 replication and pathogenesis in the presence of host innate and acquired immunity, non-human primate (NHP) models are essentially required. For this aim, three species of macaques, rhesus, cynomolgus, and pig-tailed macaques have been currently used for HIV-1 infection experiments. Macaques belong to Old World monkeys, and are susceptible to SIVmac but not to HIV-1 (). Nevertheless, rhesus macaques of Indian origin are best characterized, most utilized and most successfully used NHPs for SIV- or SHIV-based model studies on HIV-1/AIDS (; ). Although pig-tailed macaques have been quite frequently and widely used for HIV-1 model studies, they unusually rapidly progress to AIDS upon infection with SIVmac (; ; ). In addition, they lack the TRIM-mediated restriction against HIV-1 Gag-capsid (CA), and their immunological background is not so well characterized relative to that of rhesus macaques (; ; ; ). Cynomolgus macaques have not been so widely used for HIV-1/AIDS model studies (). SIVmac and SHIV are found to be less pathogenic to cynomolgus monkeys, and their immunological features are also less characterized (; ; ; ; ).
Although SIV and SHIV infect rhesus macaques and cause AIDS in the animals, their genomes are very different from HIV-1 genome. In addition to profound sequence variations, their genome compositions are distinct. Vpx gene is not present in HIV-1 genome, whereas vpu gene does not exist in SIVmac genome. SHIVs are SIVmac-derivative chimeric viruses as described above. Therefore, it has been consensus to have macaque-tropic HIV-1 derivative clones for experimental macaque infections. To overcome the species barrier against HIV-1, and generate the HIV-1 infection model system using macaques, it was absolutely necessary to pinpoint the viral genomic regions responsible for the narrow host range of HIV-1. We and others have independently and almost simultaneously identified the regions, i.e., Gag-CA and Vif, and successfully generated macaque cell-tropic HIV-1 clones [designated simian-tropic (st) HIV-1, HIV-1 derivative, or HIV-1mt (macaque-tropic)] (; ; ; ).
From the prototype HIV-1mt designated NL-DT5R (), we have modified its genome stepwise and improved its replication potential in macaque cells through sequentially introducing necessary mutations/variations by in vitro mutagenesis coupled with viral genome adaptation in cells (, , ,,; ; ; ). Of particular note and importance, we resultantly have obtained CXCR4-tropic and CCR5-tropic HIV-1rmt (rhesus macaque-tropic) clones that grow well in rhesus cells (, ; ). Figure 1 shows the basic genome structure of our HIV-1rmt clones. CXCR4-tropic MN4/LSDQgtu is demonstrated to be resistant to major anti-restriction factors (TRIM5α, APOBEC3, and tetherin) present in cynomolgus and rhesus macaque cells (), and grows best in rhesus cells among macaque-tropic HIV-1 derivative clones to the best of our knowledge ().
FIGURE 1
Growth Of HIV-1RMT Clones in Rhesus Macaques
For routine check and characterization of our HIV-1rmt clones, an immortalized lymphocyte cell line of rhesus origin was established, and designated M1.3S (
FIGURE 2

Growth property of HIV-1rmt clones in rhesus PBMCs and individuals. (A) Viral replication kinetics in rhesus PBMCs infected with CXCR4-tropic MN4/LSDQgtu, CCR5-tropic MN5/LSDQgtu, or CCR5-tropic gtu + A4CI1. PBMCs were prepared from rhesus macaques MM630 and MM631, and spin-infected with cell-free viruses obtained from transfected 293T cells as previously described (
Concluding Remarks
This is the first report to demonstrate the capability of CXCR4-tropic and CCR5-tropic HIV-1 derivative viruses to grow in rhesus macaques. Thus far, pig-tailed and cynomolgus macaques have been the only NHPs to perform in vivo infection studies on HIV-1/AIDS using viruses genetically recognizable as HIV-1 (
Issues to be addressed in the near future can be summarized as follows. (i) Obviously, to increase heterologous viral populations after infection, improving the replication capability of the present HIV-1rmt clones is required. For viral persistence in individuals, viral variations to certain extent may be essential. In this regard, our experience indicates that Gag-Pol region is still amendable by in vitro mutagenesis. Better-growing CCR5-tropic viruses are particularly necessary to mimic the HIV-1’s natural infection course in individuals. (ii) More sequences derived from distinct clinical isolates may be needed to generate new HIV-1rmt clones. This attempt may result in obtaining new useful HIV-1rmt variants. (iii) Viral adaptation in rhesus macaques, in addition to the adaptation in cell cultures, should be considered to obtain virus clones pathogenic for rhesus macaques. Finally, in conclusion, studies in these directions are in progress in our laboratories.
Animal Experiments
Monkey experiments in this study were carried out in biosafety level 3 animal facilities, in compliance with the institutional regulations approved by the Committee for Experimental Use of Non-human Primates of the Institute for Virus Research (Institute for Frontier Life and Medical Sciences since October in 2016), Kyoto University, Kyoto, Japan.
Statements
Author contributions
ND and TM designed the research, performed the experiments, and discussed the results. HM and HS performed the experiments, and discussed the results. TK discussed the results. AA designed the research, discussed the results, and wrote the manuscript. MN designed the research, performed the experiments, discussed the results, and wrote the manuscript. All authors approved its submission.
Funding
This work was supported by a Grant-in-Aid for Scientific Research (C) from Japan Society for the Promotion of Science (JSPS) (JSPS KAKENHI JP17K08860), a grant from The Imai Memorial Trust for AIDS Research to MN, and a grant from Japan Agency for Medical Research and Development, AMED (Research Program on HIV/AIDS: 17fk0410308h0003 to MN and AA).
Acknowledgments
We thank Ms. Kazuko Yoshida (Department of Microbiology, Tokushima University Graduate School of Medical Sciences) for editorial assistance. We are indebted to the Support Center for Advanced Medical Sciences, Institute of Biomedical Sciences, Tokushima University Graduate School, for experimental facilities and technical assistance.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AdachiA.GendelmanH. E.KoenigS.FolksT.WilleyR.RabsonA.et al (1986). Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.J. Virol.59284–291.
2
AkariH.FukumoriT.IidaS.AdachiA. (1999). Induction of apoptosis in Herpesvirus saimiri-immortalized T lymphocytes by blocking interaction of CD28 with CD80/CD86.Biochem. Biophys. Res. Commun.263352–356. 10.1006/bbrc.1999.1364
3
AmbroseZ.KewalRamaniV. N.BieniaszP. D.HatziioannouT. (2007). HIV/AIDS: in search of an animal model.Trends Biotechnol.25333–337. 10.1016/j.tibtech.2007.05.004
4
AuwerxJ.EsnoufR.De ClercqE.BalzariniJ. (2004). Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.Mol. Pharmacol.65244–251. 10.1124/mol.65.1.244
5
BattenC. J.De RoseR.WilsonK. M.AgyM. B.CheaS.StratovI.et al (2006). Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model.AIDS Res. Hum. Retroviruses22580–588. 10.1089/aid.2006.22.580
6
Blanco-MeloD.VenkateshS.BieniaszP. D. (2012). Intrinsic cellular defenses against human immunodeficiency viruses.Immunity37399–411. 10.1016/j.immuni.2012.08.013
7
BrowningJ.HornerJ. W.Pettoello-MantovaniM.RakerC.YurasovS.DePinhoR. A.et al (1997). Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection.Proc. Natl. Acad. Sci. U.S.A.9414637–14641. 10.1073/pnas.94.26.14637
8
BuddeM. L.WisemanR. W.KarlJ. A.HanczarukB.SimenB. B.O’ConnorD. H. (2010). Characterization of Mauritian cynomolgus macaque major histocompatibility complex class I haplotypes by high-resolution pyrosequencing.Immunogenetics62773–780. 10.1007/s00251-010-0481-9
9
CampbellE. M.HopeT. J. (2015). HIV-1 capsid: the multifaceted key player in HIV-1 infection.Nat. Rev. Microbiol.2015471–483. 10.1038/nrmicro3503
10
ChahroudiA.BosingerS. E.VanderfordT. H.PaiardiniM.SilvestriG. (2012). Natural SIV hosts: showing AIDS the door.Science3351188–1193. 10.1126/science.1217550
11
DahabiehM.BattivelliE.VerdinE. (2015). Understanding HIV latency: the road to an HIV cure.Annu. Rev. Med.66407–421. 10.1146/annurev-med-092112-152941
12
DietrichE. A.BrennanG.FergusonB.WisemanR. W.O’ConnorD.HuS. L. (2011). Variable prevalence and functional diversity of the antiretroviral restriction factor TRIMCyp in Macaca fascicularis.J. Virol.859956–9963. 10.1128/JVI.00097-11
13
DoiN.FujiwaraS.AdachiA.NomaguchiM. (2010). Growth ability in various macaque cell lines of HIV-1 with simian cell-tropism.J. Med. Invest.57284–292. 10.2152/jmi.57.284
14
DoiN.FujiwaraS.AdachiA.NomaguchiM. (2011). Rhesus M1.3S cells suitable for biological evaluation of macaque-tropic HIV/SIV clones.Front. Microbiol.2:115. 10.3389/fmicb.2011.00115
15
DoiN.OkuboA.YamaneM.SakaiY.AdachiA.NomaguchiM. (2013). Growth potentials of CCR5-tropic/CXCR4-tropic HIV-1mt clones in macaque cells.Front. Microbiol.4:218. 10.3389/fmicb.2013.00218
16
DoiN.SakaiY.AdachiA.NomaguchiM. (2017). Generation and characterization of new CCR5-tropic HIV-1rmt clones.J. Med. Invest.64272–279. 10.2152/jmi.64.272
17
DunnC. S.MehtaliM.HoudebineL. M.GutJ. P.KirnA.AubertinA. M. (1995). Human immunodeficiency virus type 1 infection of human CD4-transgenic rabbits.J. Gen. Virol.761327–1336. 10.1099/0022-1317-76-6-1327
18
EngelmanA.CherepanovP. (2012). The structural biology of HIV-1: mechanistic and therapeutic insights.Nat. Rev. Microbiol.10279–290. 10.1038/nrmicro2747
19
FosterT. L.PickeringS.NeilS. J. D. (2018). Inhibiting the ins and outs of HIV replication: cell-intrinsic antiretroviral restrictions at the plasma membrane.Front. Immunol.8:1853. 10.3389/fimmu.2017.01853
20
FreedE. O. (2015). HIV-1 assembly, release and maturation.Nat. Rev. Microbiol.13484–496. 10.1038/nrmicro3490
21
FreedE. O.MartinM. A. (2013). “Human immunodeficiency viruses: replication,” in Fields VirologyedsKnipeD. M.HowleyP. M.CohenJ. I.GriffinD. E.LambR. A.MartinM. A.et al (Philadelphia, PA: Lippincott Williams &Wilkins) 1502–1560.
22
GrütterM. G.LubanJ. (2012). TRIM5 structure, HIV-1 capsid recognition, and innate immune signaling.Curr. Opin. Virol.2142–150. 10.1016/j.coviro.2012.02.003
23
HaradaS.YoshimuraK. (2017). Driving HIV-1 into a vulnerable corner by taking advantage of viral adaptation and evolution.Front. Microbiol.8:390. 10.3389/fmicb.2017.00390
24
HatziioannouT.AmbroseZ.ChungN. P.PiatakM.Jr.YuanF.TrubeyC. M.et al (2009). A macaque model of HIV-1 infection.Proc. Natl. Acad. Sci. U.S.A.1064425–4429. 10.1073/pnas.0812587106
25
HatziioannouT.Del PreteG. Q.KeeleB. F.EstesJ. D.McNattM. W.BitzegeioJ.et al (2014). HIV-1-induced AIDS in monkeys.Science3441401–1405. 10.1126/science.1250761
26
HatziioannouT.EvansD. T. (2012). Animal models for HIV/AIDS research.Nat. Rev. Microbiol.10852–867. 10.1038/nrmicro2911
27
HatziioannouT.PrinciottaM.PiatakM.Jr.YuanF.ZhangF.LifsonJ. D.et al (2006). Generation of simian-tropic HIV-1 by restriction factor evasion.Science314:95. 10.1126/science.1130994
28
HeusingerE.KirchhoffF. (2017). Primate lentiviruses modulate NF-κB activity by multiple mechanisms to fine-tune viral and cellular gene expression.Front. Microbiol.8:198. 10.3389/fmicb.2017.00198
29
HirschV. M.OlmstedR. A.Murphey-CorbM.PurcellR. H.JohnsonP. R. (1989). An African primate lentivirus (SIVsm) closely related to HIV-2.Nature339389–392. 10.1038/339389a0
30
IgarashiT.IyengarR.ByrumR. A.Buckler-WhiteA.DewarR. L.BucklerC. E.et al (2007). Human immunodeficiency virus type 1 derivative with 7% simian immunodeficiency virus genetic content is able to establish infections in pig-tailed macaques.J. Virol.8111549–11552. 10.1128/JVI.00960-07
31
IshidaY.YonedaM.OtsukiH.WatanabeY.KatoF.MatsuuraK.et al (2016). Generation of a neutralization-resistant CCR5 tropic simian/human immunodeficiency virus (SHIV-MK38) molecular clone, a derivative of SHIV-89.6.J. Gen. Virol.971249–1260. 10.1099/jgv.0.000421
32
IshimatsuM.SuzukiH.AkiyamaH.MiuraT.HayamiM.IdoE. (2007). Construction of a novel SHIV having an HIV-1-derived protease gene and its infection to rhesus macaques: a useful tool for in vivo efficacy tests of protease inhibitors.Microbes Infect.9475–482. 10.1016/j.micinf.2007.01.005
33
KamadaK.IgarashiT.MartinM. A.KhamsriB.HatchoK.YamashitaT.et al (2006). Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells.Proc. Natl. Acad. Sci. U.S.A.10316959–16964. 10.1073/pnas.0608289103
34
KepplerO. T.WelteF. J.NgoT. A.ChinP. S.PattonK. S.TsouC. L.et al (2002). Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1.J. Exp. Med.195719–736. 10.1084/jem.20011549
35
KlattN. R.CanaryL. A.VanderfordT. H.VintonC. L.EngramJ. C.DunhamR. M.et al (2012). Dynamics of simian immunodeficiency virus SIVmac239 infection in pigtail macaques.J. Virol.861203–1213. 10.1128/JVI.06033-11
36
KuroishiA.SaitoA.ShingaiY.ShiodaT.NomaguchiM.AdachiA.et al (2009). Modification of a loop sequence between (-helices 6 and 7 of virus capsid (CA) protein in a human immunodeficiency virus type 1 (HIV-1) derivative that has simian immunodeficiency virus (SIVmac239) vif and CA alpha-helices 4 and 5 loop improves replication in cynomolgus monkey cells.Retrovirology6:70. 10.1186/1742-4690-6-70
37
MalimM. H.BieniaszP. D. (2012). HIV restriction factors and mechanisms of evasion.Cold Spring Harb. Perspect. Med.2:a006940. 10.1101/cshperspect.a006940
38
NakayamaE. E.ShiodaT. (2012). TRIM5α and species tropism of HIV/SIV.Front. Microbiol.3:13. 10.3389/fmicb.2012.00013
39
NakayamaE. E.ShiodaT. (2015). Impact of TRIM5α in vivo.AIDS291733–1743. 10.1097/QAD.0000000000000812
40
NishimuraY.MartinM. A. (2017). Of mice, macaques, and men: broadly neutralizing antibody immunotherapy for HIV-1.Cell Host Microbe22207–216. 10.1016/j.chom.2017.07.010
41
NomaguchiM.DoiN.FujiwaraS.AdachiA. (2011). “Macaque-tropic HIV-1 derivatives: a novel experimental approach to understand viral replication and evolution in vivo,” in HIV-Host Interactionsed.ChangT. L. (Rijeka: IntechOpen) 325–348. 10.5772/23624
42
NomaguchiM.DoiN.FujiwaraS.SaitoA.AkariH.NakayamaE. E.et al (2013a). Systemic biological analysis of the mutations in two distinct HIV-1mt genomes occurred during replication in macaque cells.Microbes Infect.15319–328. 10.1016/j.micinf.2013.01.005
43
NomaguchiM.YokoyamaM.KonoK.NakayamaE. E.ShiodaT.DoiN.et al (2013b). Generation of rhesus macaque-tropic HIV-1 clones that are resistant to major anti-HIV-1 restriction factors.J. Virol.8711447–11461. 10.1128/JVI.01549-13
44
NomaguchiM.YokoyamaM.KonoK.NakayamaE. E.ShiodaT.SaitoA.et al (2013c). Gag-CA Q110D mutation elicits TRIM5-independent enhancement of HIV-1mt replication in macaque cells.Microbes Infect.1556–65. 10.1016/j.micinf.2012.10.013
45
NomaguchiM.DoiN.KamadaK.AdachiA. (2008). Species barrier of HIV-1 and its jumping by virus engineering.Rev. Med. Virol.18261–275. 10.1002/rmv.576
46
NomaguchiM.DoiN.KomaT.AdachiA. (2017). Complete genome sequences of human immunodeficiency type 1 viruses genetically engineered to be tropic for rhesus macaques.Genome Announc.5:e01063-17. 10.1128/genomeA.01063-17
47
NomaguchiM.NakayamaE. E.YokoyamaM.DoiN.IgarashiT.ShiodaT.et al (2014). Distinct combinations of amino acid substitutions in N-terminal domain of Gag-capsid afford HIV-1 resistance to rhesus TRIM5α.Microbes Infect.16936–944. 10.1016/j.micinf.2014.08.017
48
OtsukiH.YonedaM.IgarashiT.MiuraT. (2014). Generation of a monkey-tropic human immunodeficiency virus type 1 carrying env from a CCR5-tropic subtype C clinical isolate.Virology461–10. 10.1016/j.virol.2014.04.037
49
PendleyC. J.BeckerE. A.KarlJ. A.BlaskyA. J.WisemanR. W.HughesA. L.et al (2008). MHC class I characterization of Indonesian cynomolgus macaques.Immunogenetics60339–351. 10.1007/s00251-008-0292-4
50
PengW.SongJ.-H.LuY.ZhengH.-Y.JiangJ.ZhengY.-T. (2018). Host restriction factors APOBEC3G/3F and other interferon-related gene expressions affect early HIV-1 infection in northern pig-tailed macaque (Macaca leonina).Front. Immunol.9:1965. 10.3389/fimmu.2018.01965
51
PriceA. J.MarzettaF.LammersM.YlinenL. M.SchallerT.WilsonS. J.et al (2009). Active site remodeling switches HIV specificity of antiretroviral TRIMCyp.Nat. Struct. Mol. Biol.161036–1042. 10.1038/nsmb.1667
52
ReimannK. A.ParkerR. A.SeamanM. S.BeaudryK.BeddallM.PetersonL.et al (2005). Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses.J. Virol.798878–8885. 10.1128/JVI.79.14.8878-8885.2005
53
SaitoA.NomaguchiM.IijimaS.KuroishiA.YoshidaT.LeeY. J.et al (2011). Improved capacity of a monkey-tropic HIV-1 derivative to replicate in cynomolgus monkeys with minimal modifications.Microbes Infect.1358–64. 10.1016/j.micinf.2010.10.001
54
SaitoA.NomaguchiM.KonoK.IwataniY.YokoyamaM.YasutomiY.et al (2013). TRIM5 genotypes in cynomolgus monkeys primarily influence inter-individual diversity in susceptibility to monkey-tropic human immunodeficiency virus type 1.J. Gen. Virol.941318–1324. 10.1099/vir.0.050252-0
55
SakuragiS.ShibataR.MukaiR.KomatsuT.FukasawaM.SakaiH.et al (1992). Infection of macaque monkeys with a chimeric human and simian immunodeficiency virus.J. Gen. Virol.732983–2987. 10.1099/0022-1317-73-11-2983
56
SharpP. M.HahnB. H. (2011). Origins of HIV and the AIDS pandemic.Cold Spring Harb. Perspect. Med.1:a006841. 10.1101/cshperspect.a006841
57
ShibataR.AdachiA. (1992). SIV/HIV recombinants and their use in studying biological properties.AIDS Res. Hum. Retroviruses8403–409. 10.1089/aid.1992.8.403
58
ShibataR.KawamuraM.SakaiH.HayamiM.IshimotoA.AdachiA. (1991). Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells.J. Virol.653514–3520.
59
SleeD. H.LasloK. L.ElderJ. H.OllmannI. R.GustchinaA.KervinenJ.et al (1995). Selectivity in the inhibition of HIV and FIV protease: inhibitory and mechanistic studies of pyrrolidine-containing (-keto amide and hydroxyethylamine core structures.J. Am. Chem. Soc.11711867–11878. 10.1021/ja00153a008
60
SmithJ. M.DaunerA.LiB.SrinivasanP.MitchellJ.HendryM.et al (2010). Generation of a dual RT Env SHIV that is infectious in rhesus macaques.J. Med. Primatol.39213–223. 10.1111/j.1600-0684.2010.00434.x
61
SpargerE. E. (2006). “FIV as a model for HIV: an overview,” in In Vivo Models of HIV Disease and ControledsFriedmanH.SpecterS.BendinelliM. (New York, NY: Springer) 149–237. 10.1007/b135975
62
ThippeshappaR.PolacinoP.KimataM. T. Y.SiwakE. B.AndersonD.WangW.et al (2011). Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1.J. Virol.853767–3779. 10.1128/JVI.02438-10
63
UberlaK.Stahl-HennigC.BöttigerD.Mätz-RensingK.KaupF. J.LiJ.et al (1995). Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.Proc. Natl. Acad. Sci. U.S.A.928210–8214. 10.1073/pnas.92.18.8210
64
VeazeyR. S.DeMariaM.ChalifouxL. V.ShvetzD. E.PauleyD. R.KnightH. L.et al (1998). Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection.Science280427–431. 10.1126/science.280.5362.427
65
WilsonS. J.WebbB. L.YlinenL. M.VerschoorE.HeeneyJ. L.TowersG. J. (2008). Independent evolution of an antiviral TRIMCyp in rhesus macaques.Proc. Natl. Acad. Sci. U.S.A.1053557–3562. 10.1073/pnas.0709003105
66
YamashitaM.EngelmanA. N. (2017). Capsid-dependent host factors in HIV-1 infection.Trends Microbiol.25741–755. 10.1016/j.tim.2017.04.004
67
YlinenL. M.PriceA. J.RasaiyaahJ.HuéS.RoseN. J.MarzettaF.et al (2010). Conformational adaptation of Asian macaque TRIMCyp directs lineage specific antiviral activity.PLoS Pathog.6:e1001062. 10.1371/journal.ppat.1001062
Summary
Keywords
HIV-1, primate model, rhesus macaque, HIV-1rmt, CXCR4-tropic, CCR5-tropic
Citation
Doi N, Miura T, Mori H, Sakawaki H, Koma T, Adachi A and Nomaguchi M (2018) CXCR4- and CCR5-Tropic HIV-1 Clones Are Both Tractable to Grow in Rhesus Macaques. Front. Microbiol. 9:2510. doi: 10.3389/fmicb.2018.02510
Received
29 August 2018
Accepted
02 October 2018
Published
18 October 2018
Volume
9 - 2018
Edited by
Koichi Watashi, National Institute of Infectious Diseases (NIID), Japan
Reviewed by
Takamasa Ueno, Kumamoto University, Japan; Takeshi Yoshida, Tokyo Medical and Dental University, Japan
Updates

Check for updates
Copyright
© 2018 Doi, Miura, Mori, Sakawaki, Koma, Adachi and Nomaguchi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Akio Adachi, adachiak@hirakata.kmu.ac.jp; adachi@tokushima-u.ac.jp Masako Nomaguchi, nomaguchi@tokushima-u.ac.jp
†These authors have contributed equally to this work
This article was submitted to Virology, a section of the journal Frontiers in Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.